abiraterone,pembrolizumab,enzalutamide,olaparib,prednisone
astrazeneca,merck,astellas,pfizer,janssen
['pembro', 'olaparib', 'agent', 'crpc']
result from the phase 3 keylink-010 trial showed no statistically significant improvement in rpfs and os when pembrolizumab and olaparib were used to treat molecularly unselected, previously treated #mcrpc vs novel hormonal agents. #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.